Send to printer »

GEN News Highlights : Feb 28, 2012

BMS, Duke to Co-Develop Candidate for Idiopathic Pulmonary Fibrosis

Initial work will progress BMS’ LPA1 receptor antagonist into Phase II.

Bristol-Myers Squibb (BMS) and Duke Translational Medicine Institute (DTMI) have established a new strategic relationship to facilitate collaborative R&D. The relationship builds on many years of collaboration in cardiology, endocrinology, and oncology, and will extend into other therapeutic areas. A steering committee comprising members of both organizations has been established to cement the partnership, identify joint opportunities, and prioritize projects.

The initial collaboration under the new relationship structure will see DTMI researchers work with BMS on clinical development of BMS-986202, an oral lysophosphatidic acid 1 (LPA1) receptor antagonist for the treatment of idiopathic pulmonary fibrosis. The two organizations will co-develop and co-implement the protocol for a Phase II study that is expected to start in 2012, as well as undertake biomarker validation studies. Subsequent joint projects will include moving new drug candidates into proof-of-concept trials, improving trial enrollment, and developing disease education programs.

“We plan for this to provide an excellent example of how we can fundamentally improve the effectiveness and transparency of academic and industry partnerships and relationships,” comments Robert M. Califf, M.D., vice-chancellor for clinical and translational research, and director of the DTMI. “Our work with BMS takes advantage of the scientific and clinical expertise within both organizations and creates opportunities by removing barriers to collaboration, employing rigorous statistical analysis, and encouraging the groups to learn from each other.”